List of Excipients in Branded Drug KEVZARA

« Back to Dashboard

KEVZARA Excipient Strategy, Formulation Patents, Biosimilar Risk, and Commercial Opportunities

Last updated: September 29, 2026

KEVZARA (sarilumab) is a subcutaneous interleukin-6 receptor inhibitor developed by Sanofi and Regeneron. Its commercial formulation uses a relatively short excipient system: L-arginine, L-histidine, polysorbate 20, and water for injection at approximately pH 6.0. The formulation creates opportunities in biosimilar development, device differentiation, stability improvement, high-concentration delivery, and manufacturing cost reduction. The principal regulatory route for a competing biological product is a U.S. biosimilar application under section 351(k), not an abbreviated new drug application or Paragraph IV certification.

What excipients are used in KEVZARA?

KEVZARA is supplied as a sterile, preservative-free solution for subcutaneous injection. The U.S. prescribing information identifies the inactive ingredients as L-arginine, L-histidine, polysorbate 20, and water for injection. The product has a pH of approximately 6.0 and is supplied in 150 mg/1.14 mL and 200 mg/1.14 mL presentations.[1]

Formulation element	KEVZARA role	Commercial relevance
Sarilumab	Fully human monoclonal antibody against the IL-6 receptor	Determines potency, aggregation behavior, and immunogenicity profile
L-arginine	Stabilizing amino acid and aggregation-control excipient	May support protein solubility and reduce self-association
L-histidine	Buffering agent	Helps maintain formulation pH during storage
Polysorbate 20	Surfactant	Limits interfacial adsorption and agitation-induced aggregation
Water for injection	Vehicle	Supports liquid, ready-to-use delivery
pH approximately 6.0	Product-condition parameter	Affects stability, viscosity, degradation, and injection tolerability

The formulation does not use a preservative. That design supports single-dose use but requires robust container-closure integrity, low-bioburden manufacturing, and tight control of particulate matter and visible contamination.

Why does KEVZARA use arginine, histidine, and polysorbate 20?

The excipient system is consistent with a liquid monoclonal-antibody formulation designed to control aggregation and maintain protein stability during refrigerated storage. Histidine provides buffering capacity, arginine can reduce protein-protein interactions, and polysorbate 20 protects against stresses caused by contact with air-liquid and container surfaces.

For a competing product, the key objective is not necessarily to copy every excipient concentration. A biosimilar developer must establish analytical and clinical similarity, while formulation differences can be acceptable if they do not affect safety, purity, potency, or immunogenicity.[2]

What dosage forms and delivery systems are protected by KEVZARA?

KEVZARA is marketed as a subcutaneous injection in a single-dose prefilled syringe and a single-dose prefilled pen or autoinjector, depending on jurisdiction and presentation. The commercial dose is commonly 200 mg every two weeks, with a 150 mg every-two-weeks dose available for patients requiring laboratory-related dose reduction.[1,3]

The delivery system creates a separate layer of commercial protection from the antibody formulation.

Prefilled syringe opportunity

A prefilled syringe has lower device complexity than an autoinjector and can support:

• Lower manufacturing cost
• Hospital and specialty-pharmacy distribution
• Compatibility with manual administration
• Use in markets where autoinjector reimbursement is limited

The main technical risks are injection force, silicone-oil interaction, needle-shield integrity, extractables and leachables, and protein adsorption to primary-container surfaces.

Autoinjector opportunity

An autoinjector can support patient self-administration and reduce administration burden. It also creates room for differentiation through:

• Shorter injection time
• Lower activation force
• Improved grip and accessibility
• Reduced needle visibility
• Feedback confirming dose completion
• Electronic adherence monitoring

Device patents, design rights, human-factors data, and combination-product regulatory requirements may be more important than the excipient composition for a differentiated follow-on product.

When does KEVZARA lose U.S. biologic exclusivity?

The FDA approved KEVZARA on May 22, 2017. Under the U.S. Biologics Price Competition and Innovation Act, the reference product generally receives 12 years of reference-product exclusivity, subject to statutory adjustments and any pediatric exclusivity.[4,5]

U.S. milestone	Date or implication
FDA approval	May 22, 2017
Reference-product exclusivity	Generally runs through approximately May 2029
Earliest practical biosimilar approval window	Approximately May 2029, subject to FDA determination
Biosimilar application pathway	Public Health Service Act section 351(k)
Small-molecule generic pathway	Not applicable
Orange Book listing	Not applicable to the biologic reference product

Patent expiry and regulatory exclusivity are separate. A biosimilar sponsor can prepare, file, and litigate before the end of the 12-year exclusivity period, but commercial approval and launch remain constrained by applicable exclusivity, patents, settlement terms, and court orders.

What is the Orange Book status of KEVZARA?

KEVZARA is not managed through the Orange Book because it is a biologic. The relevant FDA reference-product and biosimilar framework is associated with the Purple Book.[6]

As a result:

• There is no conventional Orange Book patent-listing strategy for KEVZARA.
• A competitor does not submit a Paragraph IV certification against KEVZARA’s Orange Book patents.
• Patent disputes may arise through the BPCIA patent-exchange process, district-court litigation, declaratory actions, or patent litigation involving formulation, manufacturing, or delivery systems.
• A 351(k) applicant must manage patent disclosure and litigation strategy under the BPCIA rather than the Hatch-Waxman framework.

What patents protect KEVZARA?

KEVZARA protection is likely to involve several patent categories rather than a single composition patent.

Patent category	Potential subject matter	Strategic relevance
Antibody composition	Sarilumab sequence, binding characteristics, or antigen-recognition properties	Core molecule protection; generally the strongest early patent layer
Use patents	Treatment of rheumatoid arthritis or other IL-6-mediated diseases	May affect label-specific launch strategy
Formulation patents	Protein concentration, buffer, surfactant, stabilizer, pH, or storage conditions	Directly relevant to excipient substitution
Device patents	Prefilled syringe, autoinjector, needle system, or dose-delivery mechanism	Can delay or increase the cost of device-matched launch
Manufacturing patents	Cell culture, purification, viral clearance, or polishing processes	May create process-specific freedom-to-operate issues
Packaging patents	Container closure, labeling, and cold-chain configuration	Usually secondary but relevant to commercial execution

Publicly available regulatory materials identify the marketed formulation ingredients, but a complete patent-family assessment requires review of worldwide patent records, continuations, divisionals, terminal disclaimers, prosecution histories, and any settlement agreements. The commercial risk cannot be measured from the label alone.

How strong is the KEVZARA formulation patent estate?

A formulation estate covering only the exact use of arginine, histidine, and polysorbate 20 would be vulnerable to design-around if a biosimilar uses a different buffer, surfactant, or stabilizer while maintaining comparable quality and clinical performance.

A stronger formulation estate would claim multiple parameters, such as:

• Sarilumab concentration
• Specific pH range
• Defined buffer and stabilizer combinations
• Aggregate limits after accelerated storage
• Freeze-thaw stability
• Container-closure compatibility
• Subcutaneous injection performance
• Long-term refrigerated stability

The practical strength of a formulation patent depends on claim breadth, written-description support, enablement, priority dates, and whether the claims cover commercially necessary product characteristics. Broad functional claims can attract validity challenges, while narrow concentration or pH claims may be easier to design around.

What formulation strategies create commercial opportunities?

1. Biosimilar formulation with a non-identical excipient system

A developer could evaluate alternatives to polysorbate 20, including other surfactants or surfactant systems, subject to compatibility and immunogenicity assessment. A substitution strategy may reduce dependence on formulation patents and address oxidation, peroxide formation, or particle-generation concerns associated with polysorbates.

Potential alternatives include:

• Polysorbate 80
• Poloxamers
• Low-level surfactant combinations
• Newer protein-compatible surfactants

The tradeoff is that each substitution can create new comparability work involving particles, oxidation, aggregation, potency, and anti-drug antibodies.

2. Higher-concentration sarilumab

A higher-concentration product could reduce injection volume or support a less frequent administration schedule if pharmacology and clinical data permit. The opportunity is commercially meaningful because lower injection volume can improve usability and make autoinjector delivery easier.

Technical barriers include:

• Increased viscosity
• Higher injection force
• Protein self-association
• Greater aggregation risk
• Reduced manufacturability
• Device compatibility

A high-concentration product could be protected through formulation, device, and method-of-use claims even if the active antibody is no longer composition-of-matter protected.

3. Improved refrigerated stability

KEVZARA is stored under refrigerated conditions. A formulation capable of longer room-temperature exposure could reduce cold-chain cost and improve patient convenience. Commercial claims may include:

• Longer allowable out-of-refrigerator time
• Improved excursion stability
• Lower sensitivity to transportation variation
• Extended shelf life
• Reduced wastage in specialty-pharmacy distribution

These benefits require validated stability data and may support differentiated labeling only after regulatory review.

4. Lyophilized or reconstituted presentation

A lyophilized sarilumab product could improve long-term stability in some manufacturing settings, but it would increase administration complexity and packaging cost. The opportunity is stronger in markets with weak cold-chain infrastructure than in the U.S. self-injection market.

5. Device-led differentiation

An autoinjector with lower injection force, shorter administration time, or improved usability can create commercial separation even when the formulation is biosimilar. Combination-product development should begin early because device selection affects human-factors validation, container compatibility, fill-finish operations, and regulatory timing.

Which companies are challenging KEVZARA?

No widely established U.S. commercial biosimilar competitor to sarilumab had achieved broad market presence as of the latest publicly available regulatory materials. Potential competition is more likely to emerge from large biosimilar manufacturers and specialist biologics developers with IL-6 pathway portfolios.

Relevant competitor groups include:

• Global biosimilar manufacturers with rheumatoid-arthritis portfolios
• Companies commercializing tocilizumab or other IL-6 pathway products
• Contract developers with high-concentration antibody and autoinjector capabilities
• Regional manufacturers in Europe, China, India, South Korea, and Latin America

Tocilizumab is not a sarilumab biosimilar. It is a separate IL-6 receptor-directed antibody with its own patents, clinical profile, dosing, and regulatory history. It is a therapeutic competitor, not a direct generic substitute.

What patent litigation and settlement agreements affect KEVZARA?

The primary U.S. litigation mechanism for a future sarilumab biosimilar would be the BPCIA patent-dispute process. A 351(k) applicant may face claims involving:

• Antibody sequence or binding claims
• Formulation composition
• Device components
• Manufacturing methods
• Labeling and method-of-use patents

No Paragraph IV litigation framework applies because KEVZARA is not an Orange Book small-molecule product. Publicly available information does not establish a major KEVZARA-specific settlement agreement that fixes a universally recognized early-entry date for competing sarilumab products.

A settlement, if reached, could permit entry before selected patent expirations while preserving other claims. Its commercial effect would depend on the granted license date, patent scope, launch conditions, and whether the entrant receives an interchangeable designation.

What generic entry risks exist for KEVZARA?

The main entry risk is a 351(k) biosimilar approved after reference-product exclusivity and any enforceable patent barriers expire or are settled. The likely launch scenarios are:

Scenario	Commercial effect
No approved biosimilar before 2029	KEVZARA retains reference-product pricing power longer
One biosimilar at or near exclusivity expiry	Moderate price pressure and payer-led substitution
Multiple biosimilars	Faster net-price erosion and contracting pressure
Interchangeable biosimilar	Greater pharmacy-level substitution potential where state law permits
Device-differentiated biosimilar	Reduced switching friction for self-administered patients
Formulation or manufacturing injunction	Delayed launch despite regulatory approval

Because sarilumab competes in a crowded rheumatoid-arthritis market, payer access, physician familiarity, dosing convenience, and device usability may influence market share as much as price.

How does KEVZARA compare with competing IL-6 drugs?

Product	Active ingredient	Modality	Delivery	Competitive position
KEVZARA	Sarilumab	Fully human monoclonal antibody	Subcutaneous injection	Direct IL-6 receptor competitor
ACTEMRA/ROACTEMRA	Tocilizumab	Humanized monoclonal antibody	Subcutaneous and intravenous forms	Established IL-6 franchise with broader dosage-form history
Olumiant	Baricitinib	Oral small molecule	Tablet	JAK-pathway alternative, not an IL-6 biologic
Rinvoq	Upadacitinib	Oral small molecule	Extended-release tablet	JAK-pathway competitor
Humira and biosimilars	Adalimumab	TNF inhibitor	Subcutaneous injection	Major rheumatoid-arthritis biologic competitor

KEVZARA’s excipient and device opportunities are strongest where they improve self-administration, shelf stability, injection comfort, or payer economics relative to established biologic and oral alternatives.

What is the revenue exposure from KEVZARA patent expiry?

Sanofi and Regeneron do not generally report KEVZARA as a separately prominent revenue line in the way Sanofi reports major products such as Dupixent. This limits precision in estimating product-specific revenue exposure from biosimilar entry.[7,8]

The commercial impact should be modeled using:

• U.S. net sales rather than list price
• Rheumatoid-arthritis patient share
• Dosing frequency
• Gross-to-net discounts
• Specialty-pharmacy channel mix
• Payer formulary placement
• Biosimilar count at launch
• Interchangeability status
• Device and administration costs

The product’s risk profile is more likely to be material at the franchise level than as a dominant company-wide earnings driver.

Key Takeaways

• KEVZARA uses a compact liquid formulation containing L-arginine, L-histidine, polysorbate 20, and water for injection.
• The product is a biologic, so the Purple Book and BPCIA govern follow-on competition. Orange Book Paragraph IV procedures do not apply.
• FDA approval occurred on May 22, 2017, placing the general U.S. reference-product exclusivity endpoint around May 2029.
• The strongest commercial opportunities are biosimilar formulation design, high-concentration delivery, improved refrigerated stability, and autoinjector differentiation.
• Excipient substitution can reduce formulation-patent exposure but increases comparability, stability, and immunogenicity-development risk.
• Device patents, manufacturing patents, and formulation patents may remain relevant after core molecule protection becomes less restrictive.
• Tocilizumab and JAK inhibitors are therapeutic competitors, not sarilumab biosimilars.
• Product-specific revenue exposure is difficult to isolate because KEVZARA is not generally reported as a major standalone revenue line.

FAQs

Can a sarilumab biosimilar use different excipients from KEVZARA?

Yes. A biosimilar does not necessarily need to replicate every excipient, provided the formulation supports comparable quality, purity, potency, safety, and immunogenicity outcomes.

Is KEVZARA an interchangeable biologic?

Interchangeability is a separate FDA designation from biosimilarity. A sarilumab product would need to satisfy the FDA’s interchangeability requirements before receiving that designation.

Can a competitor patent a new KEVZARA excipient combination?

Yes. A new formulation may be patentable if it meets novelty, non-obviousness, written-description, enablement, and subject-matter eligibility requirements. Patentability does not guarantee freedom to operate against earlier patents.

Does KEVZARA require cold-chain distribution?

Yes. Refrigerated storage is part of the commercial product requirements. Stability improvements that extend allowable room-temperature exposure could create a meaningful distribution and patient-use advantage.

Is a tocilizumab biosimilar a KEVZARA substitute?

No. Tocilizumab and sarilumab are different antibodies. Tocilizumab is a therapeutic competitor, while a sarilumab biosimilar must demonstrate biosimilarity to KEVZARA.

References

1. U.S. Food and Drug Administration. (2024). Kevzara (sarilumab) prescribing information. Sanofi-Aventis U.S. LLC.

2. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. U.S. Department of Health and Human Services.

3. European Medicines Agency. (2024). Kevzara: European public assessment report and product information. European Union.

4. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

7. Sanofi. (2024). Universal registration document and annual financial report. Sanofi.

8. Regeneron Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. Regeneron Pharmaceuticals, Inc.